ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Fibrocell, Castle Creek Enter Collaboration contractpharma
April 16, 2019To develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)... -
Fibrocell Announces FDA Fast Track Designation of FCX-013
americanpharmaceuticalreview
September 06, 2018Fibrocell Science announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma, a chronic, debilitating genet -
Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market
firstwordpharma
May 30, 2018EXTON, Pa., May 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases
Pharma Sources Insight January 2025
